TABLE 3.

Proportion of participants with cabotegravir concentrations >PA‐IC₉₀ and ≥4× PA‐IC₉₀ in plasma, tissues and fluids after repeat oral dosing and after a single 600‐mg intramuscular injection across sexes

Visit	Proportion, % a
	Plasma (n = 15)	Cervical tissue (n = 7)	Vaginal tissue (n = 7)	Cervicovaginal fluid (n = 7)	Rectal tissue (n = 13)	Rectal fluid (n = 12)
Oral 30 mg
Day 28
>PA‐IC90	100	100	100	86	100	100
≥4× PA‐IC90	100	71	29	43	23	100
IM 600 mg
Day 3
>PA‐IC90	100	100	71	86	69	92
≥4× PA‐IC90	100	43	29	29	8	50
Day 8
> PA‐IC90	100	86	—	100	92	100
≥4× PA‐IC90	100	43	—	29	39	100
Week 4
>PA‐IC90	100	71	—	43	77	83
≥4× PA‐IC90	100	29	—	14	0	50
Week 8
>PA‐IC90	100	43	43	14	23	67
≥4 × PA‐IC90	53	0	0	0	0	8
Week 12
>PA‐IC90	60	14	—	14	8	33
≥4 × PA‐IC90	20	0	—	0	0	17

IM, intramuscular; PA‐IC₉₀, in vitro protein‐adjusted 90% maximal inhibitory concentration.

^a PA‐IC₉₀ = 0.166 μg/mL and 4× PA‐IC₉₀ = 0.664 μg/mL.